30.00%| YTD | 1Yr | 3Yr | 5Yr | 10Yr | |
| Fund | 30.00 | 31.86 | 0.75 | 8.80 | 8.93 |
| Classification | 29.29 | 34.64 | -4.64 | 4.97 | 2.21 |
| Index (S&P 500) | 20.90 | 21.30 | -6.10 | 0.30 | -0.70 |
| % Rank in Class (1-best,100=worst) | 54 | 66 | 4 | 5 | 6 |
| Investment Objective: | International |
|---|---|
| Net Assets ($Mil) | 5,364.30 |
| Inception Date: | 5/28/98 |
| Manager Name, Tenure | Fries/Trevisani/Wang, 1998 / 2006 / 2006 |
| Expense Ratio: | 1.28% |
|
Sales Charge:
Load Type:
|
Front-End Load 4.50% 0.00% |
| Company Name | Symbol | % Net Assets |
|---|---|---|
| Teva Pharmaceutical Industries Ltd | TEVA | 3.60 |
| Standard Chartered Plc | SCBFF | 3.01 |
| Hong Kong Exchanges And Clearing Ltd | HKXCF | 2.62 |
| Novo Nordisk A/s | NONOF | 2.48 |
| Industrial And Commercial Bank Of China Ltd | IDCBF | 2.45 |
| H & M Hennes & Mauritz Ab | HMRZF | 2.39 |
| Lvmh Moet Hennessy Louis Vuitton Sa | LVMHF | 2.34 |
| Sap Ag | SAPGF | 2.33 |
| National Bank Of Greece Sa | NA | 2.31 |
| Nestle Sa | NSRGF | 2.18 |
| % of Total Holdings | 25.71 | |